<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-93980" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Congenital Myotonic Dystrophy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jain</surname>
            <given-names>Ashish</given-names>
          </name>
          <aff>Conemaugh Memorial Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Al Khalili</surname>
            <given-names>Yasir</given-names>
          </name>
          <aff>Virginia Commonwealth University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ashish Jain declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yasir Al Khalili declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-93980.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Congenital myotonic dystrophy (CMD) is an autosomal dominant neuromuscular disorder with multisystem involvement. It is a subtype of myotonic dystrophy type 1. Features include severe hypotonia and generalized muscle weakness; myotonia is classically absent in infancy. This activity will review clinical features, pathophysiology, and management strategies in CMD. It also highlights the importance of the interprofessional team in achieving the best outcomes in patients suffering from CMD.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the incidence of congenital myotonic dystrophy (CMD).</p></list-item><list-item><p>Summarize the causes of congenital myotonic dystrophy (CMD).</p></list-item><list-item><p>Outline the clinical features of congenital myotonic dystrophy (CMD).</p></list-item><list-item><p>Summarize how an interprofessional team is critical for the symptoms management, surveillance, and family support of patients with congenital myotonic dystrophy (CMD).</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=93980&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=93980">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-93980.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Congenital myotonic dystrophy (CMD) is an autosomal dominant genetic disorder caused by trinucleotide repeat expansion of CTG (cytosine-thymine-guanine) in the DMPK (dystrophia myotonica protein kinase) gene on chromosome 19q 13.3. DM is more than just muscular dystrophy as the affected individuals show the involvement of other organ systems such as cataracts, cardiac conduction anomalies, insulin resistance, the congenital form being associated with developmental disabilities, etc.<xref ref-type="bibr" rid="article-93980.r1">[1]</xref> Two major forms are described in the literature.</p>
        <p>Myotonic dystrophy type 1 (DM1), also known as Steinert disease Myotonic dystrophy type 2 (DM2), which is a milder version of DM1.</p>
        <p>Like any trinucleotide expansion repeat diseases, a larger number of repeats are associated with the severity of the disease.<xref ref-type="bibr" rid="article-93980.r2">[2]</xref><xref ref-type="bibr" rid="article-93980.r3">[3]</xref></p>
        <p><bold>Natural History:</bold><bold>&#x000a0;</bold>The incidence of&#x000a0;CMD is 1 in 47619 live births, and the mortality&#x000a0;in the neonatal period is up to 40%.&#x000a0;Severe CMD demonstrates a unique &#x0201c;biphasic&#x0201d; course; in which&#x000a0;neonatal symptoms improve/stabilize in surviving&#x000a0;neonates before adult-onset symptoms present in later life.<xref ref-type="bibr" rid="article-93980.r4">[4]</xref></p>
      </sec>
      <sec id="article-93980.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Congenital myotonic dystrophy is caused by the repeat expansion of trinucleotide "CTG" (cytosine-thymine-guanine) in the 3'-untranslated region of the myotonia dystrophy protein kinase (DMPK) gene located on chromosome 19q 13.3. Myotonic dystrophy type 2 is caused by a CCTG expansion in intron 1 of the ZNF9 (e zinc finger protein 9) gene. Parallels between these mutations indicate that microsatellite expansions in RNA can be pathogenic and cause the multisystemic features of DM1 and DM2.<xref ref-type="bibr" rid="article-93980.r5">[5]</xref>&#x000a0;Variability in the clinical expression of DM1 is thought to be caused by somatic mosaicism due to instability of CTG repeat expansion in the somatic cells during life due to an abnormality in the DNA repair.<xref ref-type="bibr" rid="article-93980.r6">[6]</xref></p>
        <p>The severity of the disease is correlated with allele size (number of repeats) with &#x0003c;30 repeats in an average healthy person to &#x0003e;11,000 repeats in the affected person; however, mild cases were reported with long expansions.<xref ref-type="bibr" rid="article-93980.r7">[7]</xref></p>
        <p>Two important terms are used in the description of autosomal dominant diseases, i.e., penetrance, and anticipation. Penetrance refers to the&#x000a0;percentage of the individuals showing signs of the disease, from the mildest to the&#x000a0;most severe phenotype. If all individuals who have a disease genotype exhibit the disease phenotype, then the disease is said to be 'fully&#x000a0;penetrant' or to have a penetrance of 100%. Anticipation refers to&#x000a0;the increased disease severity and decreased age of onset in successive generations.<xref ref-type="bibr" rid="article-93980.r8">[8]</xref><xref ref-type="bibr" rid="article-93980.r4">[4]</xref><xref ref-type="bibr" rid="article-93980.r9">[9]</xref></p>
        <p>In DM1, all clinical phenotypes except premutation exhibit full penetrance and anticipation.<xref ref-type="bibr" rid="article-93980.r10">[10]</xref><xref ref-type="bibr" rid="article-93980.r11">[11]</xref></p>
        <p>Full penetrance alleles of more than 50 are associated with disease manifestations. In CMD, repeats are usually more than 1000, compared to less than 37 in normal individuals, and 38-49 in premutation allele patients (asymptomatic). Offspring of premutation patients can inherit longer repeats, increasing the risk of disease and decreasing the age of onset in the next generations (anticipation). Contrary to the classic (adult), the maternal transmission is up to ~90% of cases, and only 9-12% are paternal. The mechanism is not yet well understood; however, maternal and intrauterine environment are considered contributing factors.<xref ref-type="bibr" rid="article-93980.r3">[3]</xref><xref ref-type="bibr" rid="article-93980.r12">[12]</xref></p>
      </sec>
      <sec id="article-93980.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Myotonic dystrophy is the most prevalent adult muscular dystrophy among the people of European ancestry with a minimum prevalence of 11.84/100,000<xref ref-type="bibr" rid="article-93980.r13">[13]</xref><xref ref-type="bibr" rid="article-93980.r14">[14]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>The incidence of CMD is&#x000a0;1 in 47619 live births, higher in specific areas (Quebec, Canada)&#x000a0;<xref ref-type="bibr" rid="article-93980.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Spain - 0.08 per 10,000 live births&#x000a0;<xref ref-type="bibr" rid="article-93980.r15">[15]</xref></p>
          </list-item>
          <list-item>
            <p>Canada - 2.1&#x000a0;in 100,000 (1&#x000a0;in 47,619) live births&#x000a0;<xref ref-type="bibr" rid="article-93980.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>South Africa - 3&#x000a0;per 100,000 live births&#x000a0;<xref ref-type="bibr" rid="article-93980.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>Taiwan 0.46/100,000 inhabitants (adult type)&#x000a0;<xref ref-type="bibr" rid="article-93980.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p>In a systemic review, the prevalence of&#x000a0;all muscular dystrophies was&#x000a0;19.8&#x000a0;to 25.1 per&#x000a0;100,000 person-years. Myotonic dystrophy (0.5&#x000a0;to 18.1&#x000a0;per100 000), Duchenne muscular dystrophy (1.7&#x000a0;to 4.2), and facioscapulohumeral&#x000a0;muscular dystrophy (3.2&#x000a0;to 4.6&#x000a0;in 100 000)&#x000a0;were the most common types.<xref ref-type="bibr" rid="article-93980.r19">[19]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-93980.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Mutation in the 3&#x02032; untranslated, noncoding region of DMPK gene, located on chromosome 19q13.3, results in the expansion of DNA (CTG) repeats. Transcription of DNA results in a mutant RNA that disrupts the splicing of CUG binding protein (CUG-BP) and Musclebind-like protein (MBNL). This leads to the sequestration of splicing factors forming ribonuclear inclusions. In turn, this disturbs cellular signaling and causes toxic effects on muscle metabolism and RNA processing. This process is known as spliceopathy.</p>
        <p>MBNL 1 protein is abundant skeletal muscle, whilst MBNL 2 in brain tissue. These proteins exhibit loss of function, as they are aggregated in the nucleus and unable to be utilized by the cell. Conversely, CUG-BP binds to cardiac troponin and exhibits gain of function via increased activation and phosphorylation. Elevated levels result in cardiac abnormalities, and abnormal insulin receptor function, elucidating the risk of diabetes. It also inhibits myoblast differentiation, resulting in loss of CIC-1 chloride channels through disruption of splicing. Defect in the splicing results in sustained muscle contraction with an inability to relax (myotonia).<xref ref-type="bibr" rid="article-93980.r4">[4]</xref><xref ref-type="bibr" rid="article-93980.r12">[12]</xref><xref ref-type="bibr" rid="article-93980.r20">[20]</xref></p>
      </sec>
      <sec id="article-93980.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Muscle biopsy is required in certain cases where genetic testing comes out to be inconclusive. Microscopy can show increased internalized nuclei (boxcar appearance), ring fibers, sarcoplasmic masses, and type 1 fiber atrophy with a pyknotic clump and type 2 fiber hypertrophy in DM1 and type 2 fiber atrophy in DM2.<xref ref-type="bibr" rid="article-93980.r21">[21]</xref><xref ref-type="bibr" rid="article-93980.r22">[22]</xref></p>
        <p><bold>Electron Microscopy Appearance:&#x000a0;</bold>Sarcoplasmic masses composed of disorganized myofibrils, dilated sarcoplasmic reticulum, and free ribosomes.</p>
      </sec>
      <sec id="article-93980.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>History</bold>
</p>
        <p>It includes detailed birth history, medical/surgical history, and 3-generation family history.</p>
        <p>Clinical features associated with CMD are as follow:<xref ref-type="bibr" rid="article-93980.r4">[4]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Prenatal: polyhydramnios, reduced fetal movements, preterm delivery &#x0003c;36 weeks, small for gestational age.</p>
          </list-item>
          <list-item>
            <p>Neonatal: hypotonia, hyporeflexia, muscle weakness (distal &#x0003e; proximal), neck muscle weakness (flexion), myopathic facies (ptosis, facial diplegia, atrophy of temporalis muscles, tent-shaped mouth), contractures, arthrogryposis, scoliosis, talipes equinovarus, visual impairment (cataract, lens opacification), respiratory distress, weak cough, sleep apnea, pulmonary hypoplasia, bronchopulmonary dysplasia, raised right hemidiaphragm, pneumothorax, recurrent infections/otitis media, aspiration pneumonia, feeding and sucking difficulties, gastroparesis, GERD, constipation/diarrhea, fecal incontinence, increased sensitivity to anesthesia (due to respiratory muscle compromise and central dysregulation of breathing), cardiac conduction disturbances, valve defects (mitral), and early death.</p>
          </list-item>
          <list-item>
            <p>Infancy and childhood, age 1&#x000a0;to 10 years: usually, they are able to walk with improvement in motor function; however, progressive weakness restarts in the 2nd decade. Myotonia (by 10 years of age), intellectual disability (50-60%), autism, ADHD, psychiatric disorders, vision problems (hyperopia, astigmatism, cataract), excessive daytime sleepiness, cardiac and endocrine complications.</p>
          </list-item>
        </list>
        <list list-type="order">
          <list-item>
            <p><bold>Respiratory:</bold>&#x000a0;respiratory difficulties are found in 50% of&#x000a0;neonates and are the main cause of neonatal&#x000a0;mortality and used&#x000a0;to distinguish between mild and severe CDM.</p>
          </list-item>
          <list-item>
            <p><bold>Musculoskeletal:</bold>&#x000a0;proximal muscle weakness in DM1&#x000a0;indicates a poor prognosis. The biphasic course in CMD shows improved/stable disease&#x000a0;until&#x000a0;adolescence/young adult with gradual deterioration.&#x000a0;Complications of muscle weakness&#x000a0;may include scoliosis and contractures&#x000a0;producing foot deformity and toe&#x000a0;walking. Bulbar muscle weakness may produce swallowing, speech, and language difficulties.</p>
          </list-item>
          <list-item>
            <p><bold>Cognition: </bold>cognitive impairment is one of the most common and challenging&#x000a0;manifestations of childhood DM1.&#x000a0;CDM patients are most affected, with IQ range&#x000a0;40&#x000a0;to 80, mean 70 (average normal 100). Cognitive impairment correlates with the severity&#x000a0;of weakness, size of CTG repeat, and maternal&#x000a0;transmission.</p>
          </list-item>
          <list-item>
            <p><bold>Sleep:</bold>&#x000a0;excessive sleep disorder and sleep apnea&#x000a0;may adversely affect&#x000a0;learning, memory, high-level cognitive processing, and&#x000a0;physical functioning,&#x000a0;exacerbating psychomotor&#x000a0;and cognitive delays.</p>
          </list-item>
          <list-item>
            <p><bold>Psychosocial:</bold>&#x000a0;50% of children have psychiatric diseases (phobia, depression, anxiety), and ADHD.&#x000a0;Avoidant&#x000a0;personality, apathy, and autistic features may&#x000a0;be present.</p>
          </list-item>
          <list-item>
            <p><bold>Cancer:&#x000a0;</bold>There is an increased risk of cancer in patients with type 1 myotonic dystrophy, including thyroid, uterine, choroidal melanoma, colon, testicular, prostate, and basal cell cancer.</p>
          </list-item>
          <list-item>
            <p><bold>Others:&#x000a0;</bold>features of&#x000a0;adult &#x0201c;classic&#x0201d; DM are not evident&#x000a0;in childhood, including cataracts, significant cardiac&#x000a0;disorders, and diabetes mellitus. Lens pathology is evident in 40% and can predict future cataract. Conduction&#x000a0;disturbances&#x000a0;observed on ECG, or valve abnormalities may be symptomatic.&#x000a0;Hypothyroidism,&#x000a0;hypogonadism, growth hormone&#x000a0;abnormalities, and&#x000a0;androgen insensitivity are&#x000a0;rare. In contrast, testicular atrophy and infertility&#x000a0;are common&#x000a0;in&#x000a0;CDM males, as are irregular menses in CDM females.&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Physical Exam:</bold>&#x000a0;vital signs, weight, height, and head circumference measurements are essential. Comprehensive neonatal exam looking for dysmorphic features, contractures, scoliosis, pulmonary and cardiac evaluation for abnormal chest rise, or murmurs. Abdominal exam for organomegaly, back for scoliosis, the musculoskeletal system for contractures, detailed neurological exam assessing mental status, cranial nerves (myopathic facies, ptosis, dysphagia, weak cry/cough/gag, respiratory failure), motor (axial and appendicular hypotonia, frog-like posture, decreased movements), reflexes, Babinski response, sensory, coordination and primitive reflexes.&#x000a0;Examine mother (myopathic facies, shake hand as myotonia prevents the prompt release of grip,&#x000a0;percussion with a reflex hammer,&#x000a0;by tapping thenar, wrist extensor will produce&#x000a0;involuntary muscle contraction with a delay in&#x000a0;relaxation, called percussion myotonia).<xref ref-type="bibr" rid="article-93980.r23">[23]</xref></p>
      </sec>
      <sec id="article-93980.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p><bold>Molecular Genetic Testing</bold> (first line): targeted analysis of the DMPK gene appears positive for a heterozygous pathogenic variant in nearly 100% of affected individuals. If the diagnosis is uncertain, the panel can be completed. The multigene panel can include testing for the DMPK CTG repeat expansion and other disorders of interest, depending on the laboratory.</p>
        <p><bold>Serum CK:</bold> normal to mildly elevated.</p>
        <p><bold>Muscle Biopsy</bold> (if negative genetic testing): increased internalized nuclei (boxcar appearance), ring fibers, sarcoplasmic masses, and type 1 fiber atrophy with a pyknotic clump.</p>
        <p><bold>Electromyography:</bold> records myopathic units (distal muscles), fibrillation potentials, and positive sharp waves. Fast runs of single-fiber discharges approaching the pattern of myotonic discharges are seen, without typical waxing and waning electrical myotonia.</p>
        <p><bold>Brain MRI:</bold>&#x000a0;may show&#x000a0;ventricular dilatation, cortical&#x000a0;atrophy, hypoplasia of the corpus callosum, and white matter abnormalities.<xref ref-type="bibr" rid="article-93980.r2">[2]</xref><xref ref-type="bibr" rid="article-93980.r8">[8]</xref><xref ref-type="bibr" rid="article-93980.r4">[4]</xref><xref ref-type="bibr" rid="article-93980.r12">[12]</xref></p>
      </sec>
      <sec id="article-93980.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Severe congenital myotonic dystrophy (CDM) will require intensive care mainly for feeding and respiratory support. Gastric/jejunum feeding tube, tracheostomy for mechanical ventilation, and splinting of talipes is occasionally commenced. Genetic counseling and end of life counseling are essential.<xref ref-type="bibr" rid="article-93980.r8">[8]</xref><xref ref-type="bibr" rid="article-93980.r23">[23]</xref><xref ref-type="bibr" rid="article-93980.r24">[24]</xref></p>
        <p>Thereafter, a multidisciplinary team approach is critical for symptom management, surveillance, and family support. The following recommendations are acquired from Consensus-based care recommendations for congenital and childhood-onset myotonic dystrophy type 1 published in 2019,<xref ref-type="bibr" rid="article-93980.r25">[25]</xref>,&#x000a0;and 2- Consensus Statement on Standard of Care for Congenital Muscular Dystrophies, published in 2014.<xref ref-type="bibr" rid="article-93980.r26">[26]</xref></p>
        <p>Neurology: disclosure of diagnosis should address five items: diagnosis, prognosis, recurrence risk, treatment plan, and family/community support. Patients should be followed by an experienced multidisciplinary team in the neuromuscular clinic. Routine surveillance every 3&#x000a0;to 4 months for infants less than 12 months, and 4&#x000a0;to 6 months in toddlers of more than 12 months. Allied health teams include nurses, physical and occupational therapists, speech and language therapists, social workers, and genetic counselors. Focusing on the financial burden and psychosocial aspects is vital.&#x000a0;Referral to ophthalmology and other services, as discussed below, is recommended.</p>
        <p>Respiratory: the primary goal is to monitor respiratory function, decrease secretions, and manage assisted ventilation. There is often an improvement in respiratory strength over time, and consideration for tracheostomy should be careful. Maintenance pulmonary therapy includes cough assist, breathe staking, etc. Pulmonary function testing includes vital capacity (&#x0003c;40% predict nocturnal hypoventilation), spirometry (&#x0003e;20% difference between sitting and supine vital capacity indicates diaphragmatic weakness and is a predictor of nocturnal hypoventilation). Other tests include peak cough flow, polysomnography, and blood gases. Pneumococcal and influenza vaccines are recommended, and palivizumab against RSV for children under two years of age.</p>
        <p>Cardiology: arrhythmias, myopathies, and structural cardiac diseases can present with lethargy, dyspnea, pallor, palpitations, and syncope. Twice yearly assessment is required with closer follow-ups in symptomatic patients.</p>
        <p>Gastroenterology: serial monitoring of nutrition and growth, feeding, GI motility (GERD, dysmotility, constipation), and oral care is recommended. Feeding tubes with or without Nissen fundoplication, laxatives, antacids, proton pump inhibitors, antiemetics, and probiotics are advisable to consider.&#x000a0;</p>
        <p>Malocclusion, teeth crowding, caries, and gingival hyperplasia (prolonged NPO) should prompt an orthodontist evaluation.</p>
        <p>Orthopedics and Rehabilitation: conservative or surgical interventions are required to manage joint contractures, scoliosis, foot, and spine deformities. Bracing, serial splinting and assisting devices to include walkers, orthotics, scooters, and wheelchairs, might be required to facilitate standing/walking/sitting.&#x000a0;Yearly evaluation is recommended, more frequent in younger children to assess motor development and function. Physical activity is essential as children will experience progressive improvements of proximal muscle strength.</p>
        <p>Pain Management: Patients with CMD are prone to developing contractures and can lead to painful spasms and joint pain. Adequate management of pain is important to achieve a good quality of life.<xref ref-type="bibr" rid="article-93980.r27">[27]</xref><xref ref-type="bibr" rid="article-93980.r28">[28]</xref><xref ref-type="bibr" rid="article-93980.r29">[29]</xref></p>
        <p>Surgical Care: pre-anesthesia assessment, prolonged postoperative monitoring, and combined procedures under single sedation are recommended as children at higher risk for complications. Avoidance of specific agents, including inhaled sedation (halothane), IV sedation (thiopentone), muscle relaxants (succinylcholine, vecuronium), neostigmine, and some chemotherapy, is essential. Propofol-induced pain can induce myotonia.<xref ref-type="bibr" rid="article-93980.r8">[8]</xref></p>
        <p>Psychiatry: Patients with CMD with their disability are prone to develop depression and anxiety and must have a psychiatry/psychologist referral as part of multidisciplinary care.<xref ref-type="bibr" rid="article-93980.r30">[30]</xref></p>
        <p>
<bold>Surveillance:<xref ref-type="bibr" rid="article-93980.r3">[3]</xref></bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Every six months: dentistry assessment</p>
          </list-item>
          <list-item>
            <p>Every year: ECG, 24-hour Holter, pulmonary function test, fasting glucose/HBA1C</p>
          </list-item>
          <list-item>
            <p>Every two years: ophthalmologic exam</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-93980.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnoses of congenital myotonic dystrophy include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Prader-Willi syndrome</p>
          </list-item>
          <list-item>
            <p>Temple syndrome</p>
          </list-item>
          <list-item>
            <p>Congenital myopathies (multiminicore, nemaline, and centronuclear)&#x000a0;<xref ref-type="bibr" rid="article-93980.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Hereditary inclusion body myopathy</p>
          </list-item>
          <list-item>
            <p>Welander distal myopathy</p>
          </list-item>
          <list-item>
            <p>Limb-girdle muscular dystrophy types 2B (dysferlinopathy) and 2L</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-93980.s11" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>
<bold>Novel Therapies </bold>
<xref ref-type="bibr" rid="article-93980.r4">[4]</xref>
<xref ref-type="bibr" rid="article-93980.r24">[24]</xref>
<xref ref-type="bibr" rid="article-93980.r31">[31]</xref>
<xref ref-type="bibr" rid="article-93980.r32">[32]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Antisense Oligonucleotides (AONs):</bold> work by degrading the CUG expansion, or by binding to CUG expansion to inhibit RNA sequestration and sites for abnormal MBNL binding.</p>
          </list-item>
          <list-item>
            <p><bold>Recombinant Adeno-associated viral (rAAV):</bold> stimulates overexpression of MBNL1, to prevent sequestration.&#x000a0;Inhibition of CUG-BP1 activity via small molecules (pentamidine) or by inhibiting protein kinase C (involved in activating CUG-BP1) can also prevent sequestration.</p>
          </list-item>
          <list-item>
            <p><bold>Clustered regularly interspaced short palindromic repeats (CRISPR/Cas): </bold>cleave and degrade CUG mRNA expansion.</p>
          </list-item>
          <list-item>
            <p><bold>Others:</bold> agents to increase muscle anabolism, such as testosterone, creatine, dehydroepiandrosterone, and recombinant insulin-like growth factor (IGF-1), and myostatin inhibitors.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-93980.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The mortality rate is up to 40% in the neonatal period due to respiratory diseases. The mean life expectancy is 45 years.<xref ref-type="bibr" rid="article-93980.r3">[3]</xref><xref ref-type="bibr" rid="article-93980.r4">[4]</xref></p>
      </sec>
      <sec id="article-93980.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Severe CDM will require intensive care mainly for feeding and respiratory support. Gastric/jejunum feeding tube and tracheostomy for mechanical ventilation are occasionally&#x000a0;required.<xref ref-type="bibr" rid="article-93980.r3">[3]</xref></p>
      </sec>
      <sec id="article-93980.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <list list-type="order">
          <list-item>
            <p>Congenital myotonic dystrophy (CMD) is a multisystem disease affecting many organs in the body. It is caused by a mutation in the DMPK gene.</p>
          </list-item>
          <list-item>
            <p>Infants appear weak, and sometimes require help with breathing and feeding.</p>
          </list-item>
          <list-item>
            <p>It is usually diagnosed by genetic testing for the targeted gene.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>There is no cure, but multiple teams will follow the patient for&#x000a0;symptoms management, surveillance, and family support.</p>
          </list-item>
          <list-item>
            <p>Unfortunately, the mortality rate is up to 40% in the neonatal period secondary&#x000a0;to respiratory failure.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-93980.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <list list-type="order">
          <list-item>
            <p>Congenital myotonic dystrophy (CMD) is an autosomal dominant neuromuscular disorder with multisystem involvement. It is a subtype of myotonic dystrophy type 1. Features include severe hypotonia and generalized muscle weakness; myotonia is classically absent in infancy.&#x000a0;
<list list-type="bullet"><list-item><p>Severe CDM will require intensive care mainly for feeding and respiratory support. Gastric/jejunum feeding tube, and tracheostomy for mechanical ventilation, and splinting of talipes is occasionally commenced.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Mutation in the DMPK gene, located on chromosome 19q13.3, results in the expansion of DNA (CTG) repeats.</p>
          </list-item>
          <list-item>
            <p>Targeted molecular genetic testing of the DMPK gene appears positive for a heterozygous pathogenic variant in nearly 100% of affected individuals.</p>
          </list-item>
          <list-item>
            <p>The multidisciplinary team approach is critical for symptom management, surveillance, and family support.</p>
          </list-item>
          <list-item>
            <p>The mortality rate is up to 40% in the neonatal period due to respiratory diseases. The mean life expectancy is 45 years.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-93980.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>As discussed previously, a multidisciplinary team approach is critical for symptom management, surveillance, and family support. Consensus-based care recommendations for congenital and childhood-onset myotonic dystrophy type 1 published in 2019,&#x000a0;and Consensus Statement on Standard of Care for Congenital Muscular Dystrophies, published in 2014&#x000a0;summarized the guidelines recommended inpatient care.<xref ref-type="bibr" rid="article-93980.r25">[25]</xref><xref ref-type="bibr" rid="article-93980.r26">[26]</xref></p>
        <p>Future clinical trials include:</p>
        <p>1&#x000a0;<bold>Natural History:</bold>&#x000a0;Trial Readiness and Endpoint Assessment in Congenital Myotonic Dystrophy (TREAT_CDM): children with CDM between ages 0&#x000a0;and 15 will be enrolled, with visits at baseline and one year to evaluate physical and cognitive function and quality of life, to extend understanding of disease progression.&#x000a0;</p>
        <p>2&#x000a0;<bold>Treatment:</bold>&#x000a0;Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy. Randomized, double-blind, placebo-controlled trials of tideglusib versus placebo in the treatment of children and adolescents 6&#x000a0;to 16 years of age with congenital DM1. The outcome is a change in Clinician-Completed Congenital DM1 Rating Scale (CDM1-RS) after 22 weeks.</p>
      </sec>
      <sec id="article-93980.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=93980&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=93980">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/congenital-myotonic-dystrophy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=93980">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/93980/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=93980">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-93980.s18">
        <title>References</title>
        <ref id="article-93980.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thornton</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Myotonic dystrophy.</article-title>
            <source>Neurol Clin</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>705</fpage>
            <page-range>705-19, viii</page-range>
            <pub-id pub-id-type="pmid">25037086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hahn</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Salajegheh</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Myotonic disorders: A review article.</article-title>
            <source>Iran J Neurol</source>
            <year>2016</year>
            <month>Jan</month>
            <day>05</day>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>46</fpage>
            <page-range>46-53</page-range>
            <pub-id pub-id-type="pmid">27141276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Turner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hilton-Jones</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Myotonic dystrophy: diagnosis, management and new therapies.</article-title>
            <source>Curr Opin Neurol</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>599</fpage>
            <page-range>599-606</page-range>
            <pub-id pub-id-type="pmid">25121518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ho</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cardamone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Farrar</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Congenital and childhood myotonic dystrophy: Current aspects of disease and future directions.</article-title>
            <source>World J Clin Pediatr</source>
            <year>2015</year>
            <month>Nov</month>
            <day>08</day>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>66</fpage>
            <page-range>66-80</page-range>
            <pub-id pub-id-type="pmid">26566479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liquori</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Ricker</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moseley</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Kress</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Naylor</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Ranum</surname>
                <given-names>LP</given-names>
              </name>
            </person-group>
            <article-title>Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9.</article-title>
            <source>Science</source>
            <year>2001</year>
            <month>Aug</month>
            <day>03</day>
            <volume>293</volume>
            <issue>5531</issue>
            <fpage>864</fpage>
            <page-range>864-7</page-range>
            <pub-id pub-id-type="pmid">11486088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pearson</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Nichol Edamura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cleary</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Repeat instability: mechanisms of dynamic mutations.</article-title>
            <source>Nat Rev Genet</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>6</volume>
            <issue>10</issue>
            <fpage>729</fpage>
            <page-range>729-42</page-range>
            <pub-id pub-id-type="pmid">16205713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r7">
          <label>7</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Schoser</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <chapter-title>Myotonic Dystrophy Type 2</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2006</year>
            <month>9</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">20301639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bird</surname>
                <given-names>TD</given-names>
              </name>
            </person-group>
            <chapter-title>Myotonic Dystrophy Type 1</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>1999</year>
            <month>9</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">20301344</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamshere</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Harley</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brook</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Brookfield</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Myotonic dystrophy: the correlation of (CTG) repeat length in leucocytes with age at onset is significant only for patients with small expansions.</article-title>
            <source>J Med Genet</source>
            <year>1999</year>
            <month>Jan</month>
            <volume>36</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-61</page-range>
            <pub-id pub-id-type="pmid">9950368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yum</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Kalsotra</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Myotonic dystrophy: disease repeat range, penetrance, age of onset, and relationship between repeat size and phenotypes.</article-title>
            <source>Curr Opin Genet Dev</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>44</volume>
            <fpage>30</fpage>
            <page-range>30-37</page-range>
            <pub-id pub-id-type="pmid">28213156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Udd</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Krahe</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The myotonic dystrophies: molecular, clinical, and therapeutic challenges.</article-title>
            <source>Lancet Neurol</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>11</volume>
            <issue>10</issue>
            <fpage>891</fpage>
            <page-range>891-905</page-range>
            <pub-id pub-id-type="pmid">22995693</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lanni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pearson</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Molecular genetics of congenital myotonic dystrophy.</article-title>
            <source>Neurobiol Dis</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>132</volume>
            <fpage>104533</fpage>
            <pub-id pub-id-type="pmid">31326502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Husebye</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Rebne</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Stokland</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Sanaker</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Bindoff</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>A hospital based epidemiological study of genetically determined muscle disease in south western Norway.</article-title>
            <source>Neuromuscul Disord</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>181</fpage>
            <page-range>181-185</page-range>
            <pub-id pub-id-type="pmid">32146000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pagola-Lorz</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Vicente</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ib&#x000e1;&#x000f1;ez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Torn&#x000e9;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Elizalde-Beiras</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Garcia-Solaesa</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Delfrade</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jeric&#x000f3;</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Epidemiological study and genetic characterization of inherited muscle diseases in a northern Spanish region.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2019</year>
            <month>Dec</month>
            <day>02</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>276</fpage>
            <pub-id pub-id-type="pmid">31791368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonz&#x000e1;lez de Dios</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez Fr&#x000ed;as</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Eg&#x000fc;es Jimeno</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gairi Tahull</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez Sabrido</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Morales Fern&#x000e1;ndez</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Pais&#x000e1;n Grisol&#x000ed;a</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pardo Romero</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Medina Rams</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Epidemiological study of Steinert's congenital myotonic dystrophy: dysmorphological characteristics].</article-title>
            <source>An Esp Pediatr</source>
            <year>1999</year>
            <month>Oct</month>
            <volume>51</volume>
            <issue>4</issue>
            <fpage>389</fpage>
            <page-range>389-96</page-range>
            <pub-id pub-id-type="pmid">10690232</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campbell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Siu</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Venance</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Congenital myotonic dystrophy: Canadian population-based surveillance study.</article-title>
            <source>J Pediatr</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>163</volume>
            <issue>1</issue>
            <fpage>120</fpage>
            <page-range>120-5.e1-3</page-range>
            <pub-id pub-id-type="pmid">23415617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lotz</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>van der Meyden</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Myotonic dystrophy. Part I. A genealogical study in the northern Transvaal.</article-title>
            <source>S Afr Med J</source>
            <year>1985</year>
            <month>May</month>
            <day>17</day>
            <volume>67</volume>
            <issue>20</issue>
            <fpage>812</fpage>
            <page-range>812-4</page-range>
            <pub-id pub-id-type="pmid">3992413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hsiao</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Jou</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Ro</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Lo</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Epidemiological and genetic studies of myotonic dystrophy type 1 in Taiwan.</article-title>
            <source>Neuroepidemiology</source>
            <year>2003</year>
            <season>Sep-Oct</season>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>283</fpage>
            <page-range>283-9</page-range>
            <pub-id pub-id-type="pmid">12902623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Theadom</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Roxburgh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Balalla</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Higgins</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bhattacharjee</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Krishnamurthi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Feigin</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of muscular dystrophies: a systematic literature review.</article-title>
            <source>Neuroepidemiology</source>
            <year>2014</year>
            <volume>43</volume>
            <issue>3-4</issue>
            <fpage>259</fpage>
            <page-range>259-68</page-range>
            <pub-id pub-id-type="pmid">25532075</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bissay</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Van Malderen</surname>
                <given-names>SCH</given-names>
              </name>
            </person-group>
            <article-title>What the internist should know about hereditary muscle channelopathies.</article-title>
            <source>Acta Clin Belg</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>73</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-6</page-range>
            <pub-id pub-id-type="pmid">29088983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Day</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Ricker</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Dick</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Kress</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Beilman</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Dalton</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ranum</surname>
                <given-names>LP</given-names>
              </name>
            </person-group>
            <article-title>Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum.</article-title>
            <source>Neurology</source>
            <year>2003</year>
            <month>Feb</month>
            <day>25</day>
            <volume>60</volume>
            <issue>4</issue>
            <fpage>657</fpage>
            <page-range>657-64</page-range>
            <pub-id pub-id-type="pmid">12601109</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lieberman</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Fischbeck</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>Triplet repeat expansion in neuromuscular disease.</article-title>
            <source>Muscle Nerve</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>23</volume>
            <issue>6</issue>
            <fpage>843</fpage>
            <page-range>843-50</page-range>
            <pub-id pub-id-type="pmid">10842259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heatwole</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Statland</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Logigian</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <article-title>The diagnosis and treatment of myotonic disorders.</article-title>
            <source>Muscle Nerve</source>
            <year>2013</year>
            <month>May</month>
            <volume>47</volume>
            <issue>5</issue>
            <fpage>632</fpage>
            <page-range>632-48</page-range>
            <pub-id pub-id-type="pmid">23536309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thornton</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Carrell</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Myotonic dystrophy: approach to therapy.</article-title>
            <source>Curr Opin Genet Dev</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>44</volume>
            <fpage>135</fpage>
            <page-range>135-140</page-range>
            <pub-id pub-id-type="pmid">28376341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Aldana</surname>
                <given-names>EZ</given-names>
              </name>
              <name>
                <surname>Angeard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ashizawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Berggren</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Marini-Bettolo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Duong</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ekstr&#x000f6;m</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Sansone</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hellerstein</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Consensus-based care recommendations for congenital and childhood-onset myotonic dystrophy type 1.</article-title>
            <source>Neurol Clin Pract</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>443</fpage>
            <page-range>443-454</page-range>
            <pub-id pub-id-type="pmid">31750030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Bonnemann</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Rutkowski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sejersen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bellini</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Battista</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Florence</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Schara</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Schuler</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Wahbi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Aloysius</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bash</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>B&#x000e9;roud</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bertini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bushby</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Connolly</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Deconinck</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Desguerre</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Eagle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Estournet-Mathiaud</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ferreiro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fujak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goemans</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Iannaccone</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Jouinot</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Main</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Melacini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mueller-Felber</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Muntoni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Rahbek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Quijano-Roy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sewry</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Storhaug</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Simonds</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tseng</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vajsar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vianello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zeller</surname>
                <given-names>R</given-names>
              </name>
              <collab>International Standard of Care Committee for Congenital Muscular Dystrophy</collab>
            </person-group>
            <article-title>Consensus statement on standard of care for congenital muscular dystrophies.</article-title>
            <source>J Child Neurol</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>25</volume>
            <issue>12</issue>
            <fpage>1559</fpage>
            <page-range>1559-81</page-range>
            <pub-id pub-id-type="pmid">21078917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Malinowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chopra</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Varshney</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Deer</surname>
                <given-names>TR</given-names>
              </name>
            </person-group>
            <article-title>Intrathecal drug delivery for pain management: recent advances and future developments.</article-title>
            <source>Expert Opin Drug Deliv</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>16</volume>
            <issue>8</issue>
            <fpage>815</fpage>
            <page-range>815-822</page-range>
            <pub-id pub-id-type="pmid">31305165</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deer</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chakravarthy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Neurostimulation for Intractable Chronic Pain.</article-title>
            <source>Brain Sci</source>
            <year>2019</year>
            <month>Jan</month>
            <day>24</day>
            <volume>9</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">30682776</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deer</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Grider</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Lamer</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Pope</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Falowski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Provenzano</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Slavin</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carayannopoulos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Harned</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Hagedorn</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bolash</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Arle</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Kapural</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Amirdelfan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liem</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Carlson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Malinowski</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Bendel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aiyer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Valimahomed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Antony</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fishman</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Al-Kaisy</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Christelis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rosenquist</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Mekhail</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>A Systematic Literature Review of Spine Neurostimulation Therapies for the Treatment of Pain.</article-title>
            <source>Pain Med</source>
            <year>2020</year>
            <month>Nov</month>
            <day>07</day>
            <volume>21</volume>
            <issue>7</issue>
            <fpage>1421</fpage>
            <page-range>1421-1432</page-range>
            <pub-id pub-id-type="pmid">32034422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bungener</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jouvent</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Delaporte</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Psychopathological and emotional deficits in myotonic dystrophy.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>1998</year>
            <month>Sep</month>
            <volume>65</volume>
            <issue>3</issue>
            <fpage>353</fpage>
            <page-range>353-6</page-range>
            <pub-id pub-id-type="pmid">9728948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bisset</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Stepniak-Konieczna</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Zavaljevski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Chamberlain</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy.</article-title>
            <source>Hum Mol Genet</source>
            <year>2015</year>
            <month>Sep</month>
            <day>01</day>
            <volume>24</volume>
            <issue>17</issue>
            <fpage>4971</fpage>
            <page-range>4971-83</page-range>
            <pub-id pub-id-type="pmid">26082468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93980.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raaijmakers</surname>
                <given-names>RHL</given-names>
              </name>
              <name>
                <surname>Ripken</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ausems</surname>
                <given-names>CRM</given-names>
              </name>
              <name>
                <surname>Wansink</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>CRISPR/Cas Applications in Myotonic Dystrophy: Expanding Opportunities.</article-title>
            <source>Int J Mol Sci</source>
            <year>2019</year>
            <month>Jul</month>
            <day>27</day>
            <volume>20</volume>
            <issue>15</issue>
            <pub-id pub-id-type="pmid">31357652</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
